gene editing

Allergan and Editas exercise CRISPR option
Allergan and Editas exercise CRISPR option
Biopharma Dive
Allergan
Editas Medicine
CRISPR
EDIT-101
gene editing
Flag link:
Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer
Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer
Motley Fool
Intellia Therapeutics
gene editing
CRISPR
Flag link:
Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds
Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds
Stat
CRISPR
gene editing
Flag link:
CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds
CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds
Stat
CRISPR
cancer
gene editing
Flag link:
How CRISPR tools are unlocking new ways to fight disease
How CRISPR tools are unlocking new ways to fight disease
Phys.org
CRISPR
gene editing
Flag link:
A Deep Dive Into The Latest CRISPR Controversy: Here’s What You Should Know
A Deep Dive Into The Latest CRISPR Controversy: Here’s What You Should Know
Motley Fool
CRISPR
gene editing
Flag link:
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
Stat
CRISPR
gene editing
cancer
Flag link:
Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round
Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round
CP Wire
Beam Therapeutics
gene editing
CRISPR
Flag link:
Gene editing shows promise in combating HIV reservoirs
Gene editing shows promise in combating HIV reservoirs
Fierce Biotech
gene editing
HIV
Flag link:
CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys
CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys
MIT Technology Review
gene editing
clinical trials
CRISPR
Flag link:
No Data Yet, But Homology Upsizes IPO and Raises $144M
No Data Yet, But Homology Upsizes IPO and Raises $144M
Xconomy
Homology Med
IPOs
gene editing
Flag link:
[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important
[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important
Motley Fool
Gilead Sciencs
gene editing
Sangamo Therapeutics
cancer
Flag link:
Startup making Cas9 proxy for gene editing gets $55M to develop tools/software
Startup making Cas9 proxy for gene editing gets $55M to develop tools/software
Endpoints
gene editing
Cas9
Inscripta
CRISPR
Flag link:
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Xconomy
cell therapy
Gilead Sciences
Sangama
CAR-T
gene editing
Flag link:
Sarepta is making a bold bet on genetic medicine
Sarepta is making a bold bet on genetic medicine
Marketwatch
Sarepta Therapeutics
gene therapy
gene editing
genetic medicine
Flag link:
Disruptor Alert: These 5 Companies Are Changing Healthcare
Disruptor Alert: These 5 Companies Are Changing Healthcare
Motley Fool
CRISPR Therapeutics
Editas Medicine
Illumina
IBM
Intellia Therapeutics
gene editing
gene sequencing
artificial intelligence
Flag link:
Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech
Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech
Endpoints
Sangamo
gene editing
Hunter Syndrome
CRISPR
SB-913
Flag link:
Anti-CRISPR Proteins Could Improve Accuracy of Gene Editing
Anti-CRISPR Proteins Could Improve Accuracy of Gene Editing
Xtalks
gene editing
CRISPR
anti-CRISPR proteins
Flag link:
5 Trends affecting gene therapy development
5 Trends affecting gene therapy development
BioPharma Dive
gene therapy
gene editing
patents
ethics
drug development
Flag link:
'The Biggest Biotech Discovery Of The Century'
'The Biggest Biotech Discovery Of The Century'
Seeking Alpha
biotech
CRISPR
gene editing
Flag link:

Pages